Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001696029 XXXXXXXX LIVE 9 Common Shares, par value (euro)0.12 per share 12/10/2025 false 0001809122 N2451R105 CUREVAC N.V. Friedrich-Miescher-Strasse 15 Tubingen 2M 72076 Brian S. North, Esquire (215) 665-8700 Buchanan Ingersoll & Rooney PC 50 South 16th Street, Suite 3200 Philadelphia PA 19102 Dr. Christina Eschenfelder 49 621 4256-275 RITTERSHAUS Harrlachweg 4 Mannheim 2M 68163 0001696029 N dievini Hopp BioTech holding GmbH & Co. KG a OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 PN Y DH-LT-Investments GmbH a OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 OO Y DH-Capital GmbH & Co. KG OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 PN Y OH Beteiligungen GmbH & Co. KG OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 PN Y Dietmar Hopp a PF N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 IN Y Oliver Hopp OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 IN Y Daniel Hopp OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 IN Y DHFS II Holding GmbH & Co. KG a OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 OO Y Zweite DH Verwaltungs GmbH a OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 OO Common Shares, par value (euro)0.12 per share CUREVAC N.V. Friedrich-Miescher-Strasse 15 Tubingen 2M 72076 This Amendment No. 9 to Schedule 13D (this "Amendment") amends the Schedule 13D filed with the Comment: Securities and Exchange Commission on August 24, 2020 by the Reporting Persons (the "Initial Statement" and, as amended and supplemented through the date of this Amendment, collectively, the "Statement") with respect to common shares, par value (euro)0.12 per share (the "Shares") of CureVac N.V., a Dutch public company (the "Issuer"). This Amendment is being filed to reflect the completion of the Reporting Persons' exchange all of the Shares beneficially owned by them pursuant the exchange offer (the "Exchange Offer") contemplated by the Tender and Support Agreement dated June 12, 2025 (the "Tender and Support Agreement") by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-LT-Investments GmbH ("DH-LT Investments"), Zweite DH Verwaltungs GmbH ("Zweite DH"), and DH-Assets GmbH & Co. KG with BioNTech SE, a European stock corporation ("BioNTech"). This Amendment is also being filed to reflect the expected termination of the Shareholders' Agreement dated as of June 16, 2020, by and among KfW, dievini, and Dietmar Hopp and as amended by Supplement to the Shareholders' Agreement dated as of August 14, 2020 and by Second Supplement to the Shareholders' Agreement dated as of January 13, 2022 (as amended from time to time, the "Shareholders' Agreement") on or about December 15, 2025. This Amendment is the final amendment to the Schedule 13D by the Reporting Persons and constitutes an "exit filing" by them. The Reporting Persons have tendered all of their Shares into the Exchange Offer pursuant to the Tender and Support Agreement. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Shares tendered by the Reporting Persons were accepted for exchange and transferred to BioNTech in a capital increase for the issue of shares in BioNTech underlying the American Depository Shares of BioNTech offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, the Reporting Persons no longer beneficially own, or otherwise hold, any securities of the Issuer. The Reporting Persons expect to receive full consideration to which they are entitled under the Exchange Offer (the "Completion") on or about December 15, 2025. Pursuant to an agreement dated October 29, 2025 among the parties to the Shareholders' Agreement, the Shareholders' Agreement will terminate upon the Completion. The foregoing description of the Tender and Support Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to such agreement. A copy of the form of Tender and Support Agreement is incorporated by reference to Exhibit 99.3 to the Reporting Persons' Amendment 8 to Schedule 13D filed with the SEC on June 16, 2025. The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The Reporting Persons tendered all of their Shares in the Exchange Offer and, as a result of the issuance by BionTech of its securities in the Exchange Offer on December 10, 2025, the Reporting Persons no longer beneficially own any Shares. The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Other than the transaction described in Item 5(a) no Reporting Person has effected any transaction in the Shares during the past sixty (60) days Not applicable. December 10, 2025. 99.1 Power of Attorney (Incorporated by reference to Exhibit 1 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the SEC on May 5, 2022). 99.2 Joint Filing Agreement (Incorporated by reference to Exhibit 2 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the SEC on May 5, 2022). 99.3 Tender and Support Agreement (Incorporated by reference to Exhibit 99.3 to Amendment No. 8 to Schedule 13D filed by the Reporting Persons with the SEC on June 16, 2022). dievini Hopp BioTech holding GmbH & Co. KG /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025 DH-LT-Investments GmbH /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025 DH-Capital GmbH & Co. KG /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025 OH Beteiligungen GmbH & Co. KG /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025 Dietmar Hopp /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder as attorney-in-fact 12/12/2025 Oliver Hopp /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder as attorney-in-fact 12/12/2025 Daniel Hopp /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder as attorney-in-fact 12/12/2025 DHFS II Holding GmbH & Co. KG /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025 Zweite DH Verwaltungs GmbH /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025